Headquartered in Rockville, MD Fiscal year ends December NASDAQ: RGNX regenxbio.com
REGENXBIO is a clinical-stage biotechnology company focused on developing one-time gene therapies using its proprietary adeno-associated virus (AAV) platform. The company's late-stage pipeline targets rare and retinal diseases, including RGX-202 for Duchenne muscular dystrophy, surabgene lomparvovec (ABBV-RGX-314, developed with AbbVie) for wet age-related macular degeneration and diabetic retinopathy, and NAVSUNLI (RGX-121, partnered with Nippon Shinyaku) for Hunter syndrome (MPS II). REGENXBIO's AAV technology platform has been widely adopted, notably underpinning Novartis's ZOLGENSMA for spinal muscular atrophy and ITVISMA, generating royalty revenue streams. The company operates an in-house Manufacturing Innovation Center for commercial-scale production and derives revenue from license and royalty agreements as well as collaboration service fees. REGENXBIO was founded in 2009 and trades on Nasdaq under the ticker RGNX. Updated
Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS | GS Price Prediction) has to be atop the list. The investment banking giant has accumulated some of…
REGENXBIO is a clinical-stage biotechnology company focused on developing one-time gene therapies using its proprietary adeno-associated virus (AAV) platform.
The Wall Street consensus 12-month price target for RGNX is $23.58.
